8-K: Scholar Rock Reports Full Year 2024 Financial Results and Highlights Business Progress

Scholar Rock submitted its Biologics License Application (BLA) for apitegromab in the U.S. for spinal muscular atrophy (SMA) patients and anticipates a U.S. launch in Q4 2025.

Summary

• Scholar Rock reported its full year 2024 financial results and provided a business update.
• The company submitted a BLA for apitegromab to the FDA in January 2025 and remains on track to submit a marketing authorisation application (MAA) to the EMA in Q1 2025.
• Topline data from the Phase 2 EMBRAZE trial evaluating apitegromab in adult patients with obesity receiving tirzepatide is expected in Q2 2025.
• An IND application for SRK-439, a myostatin inhibitor for cardiometabolic indications, is anticipated in Q3 2025.
• Scholar Rock ended 2024 with approximately $437 million in cash, cash equivalents, and marketable securities.
• The company expects its cash to fund operations into the fourth quarter of 2026.
• Net loss for the full year 2024 was $246.3 million, or $2.47 per share, compared to a net loss of $165.8 million, or $1.99 per share, for the full year 2023.
• Research and development expense was $184.6 million for the year ended December 31, 2024, compared to $121.9 million for the year ended December 31, 2023.
• General and administrative expense was $67.5 million for the year ended December 31, 2024, compared to $49.4 million for the year ended December 31, 2023.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with regulatory submissions on track, promising clinical trial data, and a strong cash position; the increased net loss is a concern, but the overall tone is optimistic.

Positives

• The company has a strong cash position of $437 million, expected to fund operations into Q4 2026.
• Apitegromab has received Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the FDA, and PRIME and Orphan Medicinal Product designations from the EMA.
• The company completed a $345 million public offering in October 2024.
• Scholar Rock is planning to initiate Phase 2 OPAL clinical trial in SMA patients under two years of age in 3Q 2025.
• The company is expanding development of apitegromab in other rare neuromuscular disorders.

Negatives

• The company reported a net loss of $246.3 million for the full year 2024, which is higher than the $165.8 million loss in 2023.
• The company did not record any revenue for the year ended December 31, 2024, or for the year ended December 31, 2023.

Risks

• The success of clinical trials is not guaranteed, and results may not be predictive of future outcomes.
• Regulatory approvals are not guaranteed and may be delayed.
• The company faces competition from other companies developing similar products.
• The company depends on third parties for development and manufacture of product candidates.
• The company needs to manage expenses and obtain additional funding when needed.

Future Outlook

Scholar Rock anticipates a U.S. commercial launch of apitegromab in Q4 2025, submission of the MAA in Q1 2025, topline data from the EMBRAZE trial in Q2 2025, and filing of the IND application for SRK-439 in Q3 2025; the company expects its cash to fund operations into the fourth quarter of 2026.

Management Comments

• Following positive topline results from the SAPPHIRE trial demonstrating apitegromabs potential to transform the lives of people living with spinal muscular atrophy while receiving SMN-targeted therapies, we have entered 2025 with tremendous momentum, said Jay Backstrom, M.D., MPH, President & Chief Executive Officer of Scholar Rock.
• We have submitted our BLA and remain on track to submit our MAA later this quarter and we are working with urgency to prepare for our anticipated commercial launch.
• In parallel, we plan to initiate our OPAL study to explore earlier treatment for SMA patients under two years of age and have two critical milestones ahead for our cardiometabolic program with the topline data readout of the EMBRAZE trial and IND application for SRK-439.
• Scholar Rock has entered 2025 from a position of financial strength, and the successful public offering completed in October 2024 will support both the planned commercial launch of apitegromab in SMA and the advancement our portfolio of highly selective myostatin inhibition programs, said Ted Myles, Chief Operating Officer and Chief Financial Officer of Scholar Rock.
• The organization is well positioned to bring apitegromab to patients and to achieve key milestones in the year ahead.

Industry Context

The announcement highlights Scholar Rock's progress in the competitive biopharmaceutical industry, particularly in SMA and cardiometabolic disorders, where there is a high unmet need for new treatments; the company is positioning itself to be a leader in muscle-targeted therapies.

Comparison to Industry Standards

• The SAPPHIRE trial results, showing a statistically significant improvement in motor function for SMA patients, position apitegromab as a potential competitor to existing SMN-targeted therapies like nusinersen (Biogen's Spinraza), risdiplam (Roche's Evrysdi), and gene therapies like onasemnogene abeparvovec (Novartis' Zolgensma).
• The EMBRAZE trial, evaluating apitegromab in combination with tirzepatide, aims to address the issue of muscle loss associated with GLP-1 receptor agonists, which are increasingly used for weight loss; this could differentiate Scholar Rock from companies solely focused on GLP-1 RAs, such as Eli Lilly and Novo Nordisk.
• The development of SRK-439 as a myostatin inhibitor for obesity aligns with the growing interest in muscle-targeted therapies for metabolic disorders, potentially competing with other companies exploring similar approaches.

Management Changes

Stakeholder Impact

• Shareholders: The company's progress and financial stability are positive for shareholders.
• Patients: The potential launch of apitegromab offers a new treatment option for SMA patients.
• Employees: The company's growth and expansion create opportunities for employees.
• Creditors: The company's strong cash position reduces credit risk.

Next Steps

• Submit MAA to the EMA in Q1 2025.
• Report topline data from the Phase 2 EMBRAZE trial in Q2 2025.
• File IND application for SRK-439 in Q3 2025.
• Initiate Phase 2 OPAL clinical trial in SMA patients under two years of age in 3Q 2025.
• Prepare for U.S. commercial launch of apitegromab in Q4 2025.

Key Dates